Topics

Orphan drug status granted to microbiome-derived therapy for HCC

05:56 EDT 29 Oct 2019 | SmartBrief

SFA Therapeutics' investigational hepatocellular carcinoma treatment SFA001 was awarded orphan drug status by the FDA.  -More

Original Article: Orphan drug status granted to microbiome-derived therapy for HCC

NEXT ARTICLE

More From BioPortfolio on "Orphan drug status granted to microbiome-derived therapy for HCC"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...